J Tayama1, S Ogawa2, N Nakaya3, T Sone4, T Hamaguchi5, A Takeoka2, K Hamazaki6, H Okamura7, J Yajima8, M Kobayashi2, M Hayashida2, S Shirabe2. 1. Graduate School of Education, Nagasaki University, Nagasaki, Japan; Center for Health and Community Medicine, Nagasaki University, Nagasaki, Japan. Electronic address: jtayama@nagasaki-u.ac.jp. 2. Center for Health and Community Medicine, Nagasaki University, Nagasaki, Japan. 3. Tohoku Medical Megabank Organization, Tohoku University, Miyagi, Japan. 4. Department of Rehabilitation, Faculty of Health Science, Tohoku Fukushi University, Miyagi, Japan. 5. Department of Occupational Therapy, School of Health and Social Services Saitama Prefectural University, Saitama, Japan. 6. Department of Public Health, Faculty of Medicine, University of Toyama, Toyama, Japan. 7. Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Fukuoka, Japan. 8. Faculty of Literature, Beppu University, Japan.
Abstract
BACKGROUND: This study assessed whether a combined intervention of omega-3 polyunsaturated fatty acids (PUFAs) and psychoeducation better improved mild to moderate depression in workers compared to psychoeducation alone. METHODS: This study was a double-blinded, parallel group, randomized controlled trial that compared the intervention group, receiving omega-3 fatty acids, with a control group, receiving a placebo supplement. Participants receiving omega-3 fatty acids took 15 × 300 mg capsules per day for 12 weeks. The total daily dose of omega-3 PUFAs was 500 mg docosahexaenoic acid and 1000 mg eicosapentaenoic acid (EPA). The Beck Depression Inventory®-II (BDI-II) was used to assess the severity of depression after treatment. RESULTS: After 12 weeks of treatment, BDI-II scores were significantly lower in the placebo and omega-3 group, when compared to their respective baseline scores (Placebo: t = - 4.6, p < 0.01; Omega-3: t = - 7.3, p < 0.01). However, after 12 weeks of treatment, we found no significant difference between both groups with respect to changes in the BDI-II scores (0.7; 95% CI, - 0.7 to 2.1; p = 0.30). LIMITATIONS: This study did not measure blood omega-3 fatty acid concentration and presented a high-dropout rate. Moreover, our results may not be generalizable to other regions. CONCLUSIONS: The results show that a combination of omega-3 fatty acids and psychoeducation and psychoeducation alone can contribute to an improvement in symptoms in people with mild to moderate depression. However, there is no difference between the interventions in ameliorating symptoms of depression.
RCT Entities:
BACKGROUND: This study assessed whether a combined intervention of omega-3 polyunsaturated fatty acids (PUFAs) and psychoeducation better improved mild to moderate depression in workers compared to psychoeducation alone. METHODS: This study was a double-blinded, parallel group, randomized controlled trial that compared the intervention group, receiving omega-3 fatty acids, with a control group, receiving a placebo supplement. Participants receiving omega-3 fatty acids took 15 × 300 mg capsules per day for 12 weeks. The total daily dose of omega-3 PUFAs was 500 mg docosahexaenoic acid and 1000 mg eicosapentaenoic acid (EPA). The Beck Depression Inventory®-II (BDI-II) was used to assess the severity of depression after treatment. RESULTS: After 12 weeks of treatment, BDI-II scores were significantly lower in the placebo and omega-3 group, when compared to their respective baseline scores (Placebo: t = - 4.6, p < 0.01; Omega-3: t = - 7.3, p < 0.01). However, after 12 weeks of treatment, we found no significant difference between both groups with respect to changes in the BDI-II scores (0.7; 95% CI, - 0.7 to 2.1; p = 0.30). LIMITATIONS: This study did not measure blood omega-3 fatty acid concentration and presented a high-dropout rate. Moreover, our results may not be generalizable to other regions. CONCLUSIONS: The results show that a combination of omega-3 fatty acids and psychoeducation and psychoeducation alone can contribute to an improvement in symptoms in people with mild to moderate depression. However, there is no difference between the interventions in ameliorating symptoms of depression.
Authors: Katherine M Appleton; Philip D Voyias; Hannah M Sallis; Sarah Dawson; Andrew R Ness; Rachel Churchill; Rachel Perry Journal: Cochrane Database Syst Rev Date: 2021-11-24
Authors: J Douglas Bremner; Kasra Moazzami; Matthew T Wittbrodt; Jonathon A Nye; Bruno B Lima; Charles F Gillespie; Mark H Rapaport; Bradley D Pearce; Amit J Shah; Viola Vaccarino Journal: Nutrients Date: 2020-08-13 Impact factor: 5.717
Authors: Maike Wolters; Annkathrin von der Haar; Ann-Kristin Baalmann; Maike Wellbrock; Thomas L Heise; Stefan Rach Journal: Nutrients Date: 2021-03-25 Impact factor: 5.717